Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Investing in penny stocks can be a thrilling way to explore the potential for substantial gains. Despite their inherent risks, these stocks often appeal to adventurous investors looking to diversify their portfolios without breaking the bank.
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue growth, but guidance offered little new information. A lipid lurker marketing campaign shows early top of the funnel success, but there is little data yet to demonstrate bottom funnel performance.
